
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana is forecasted to achieve an increased earnings per share (EPS) of $17.06 for 2025, up from a previous estimate of $16.26, which reflects positive second-quarter results and revised guidance. The company's margin initiatives are expected to contribute to year-over-year earnings growth in 2027, despite the assumption that its Star ratings will remain stable without a recovery of bonus payments. Additionally, Humana's above-industry Medicare Advantage star rating positions the company favorably in a changing regulatory environment, enhancing its competitive standing in the health insurance market.
Bears say
The financial outlook for Humana is bleak, with management projecting a slight decline in earnings per share (EPS) for 2026 compared to 2025, primarily due to challenges associated with Star ratings, despite efforts to implement margin initiatives. There are significant downside risks that could further impact the company, including increased utilization in Medicare Advantage (MA), heightened competition, inadequate reimbursement rates, and a potential decline in membership for the Part D plan (PDP). Additionally, projections indicate that FY27 EPS could fall approximately 10% below estimates due to necessary investments aimed at recovering Star ratings, highlighting potential vulnerabilities in growth within its Healthcare Services segment.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares